Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.46 |
| ▸ | USP2 | O75604 | 8/20 | 0.46 |
| ▸ | CASP1 | P29466 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 6/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | GLA | P06280 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21553003 | 0.84 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP3A4USP2CASP1 | |
| SCHEMBL21552863 | 0.84 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP3A4USP2CASP1 | |
| SCHEMBL21552954 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP3A4USP2CASP1 | |
| SCHEMBL21552952 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP3A4USP2CASP1 | |
| SCHEMBL21553169 | 0.79 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP3A4USP2CASP1 | |
| SCHEMBL21553074 | 0.76 | KDM1A (0.38) | ALDH1A1CYP1A2CYP3A4USP2CASP1 | |
| SCHEMBL21552996 | 0.76 | ADORA2B (0.48) | CREBBPADORA2AADORA2BADORA1MEN1 | |
| SCHEMBL1051534 | 0.71 | ADORA2A (0.44) | CYP3A4HSD17B10ADORA2AADORA2BADORA1 | |
| SCHEMBL17385332 | 0.70 | MAPT (0.50) | ALDH1A1HSD17B10KDM4ECREBBPADORA2A | |
| SCHEMBL27809117 | 0.70 | MAPT (0.58) | ALDH1A1CYP1A2CYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790867-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112513020-B | KDM1A inhibitors for the treatment of diseases | 伊美格生物科学公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | Imago Biosciences. Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3790867-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| CN-112513020-A | KDM1A inhibitors for the treatment of disease | 伊美格生物科学公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2019217972-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019217972-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | ALDH1A1 839/4885CYP1A2 3288/4885CYP3A4 4184/4885 |
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | ALDH1A1 839/4885CYP1A2 3288/4885CYP3A4 4184/4885 |
| US-20210115023-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1A, KDM1B, KDM2A | ALDH1A1 599/4885CYP1A2 3042/4885CYP3A4 4123/4885 |
| US-11578059-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | ALDH1A1 839/4885CYP1A2 3288/4885CYP3A4 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.